Darzalex Faspro 1800mg Injection

• Multiple myeloma

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Darzalex Faspro 1800mg Injection also causes some adverse impact on the body, most of which resolve without any medical attention. Some common side effects include:

• Gastrointestinal toxicity
• Headache
• Decreased appetite
• Joint inflammation
• Chest pain
• Decreased potassium level in blood
• Weakness
• Infection
• Muscle spasm
• Insomnia (difficulty sleeping)
• Peripheral edema
• Infusion reaction
• Altered blood cell count
• Respiratory tract infection
• Increased liver enzymes
• Fatigue
• Back pain

Seek medical attention in case of any unusual or severe side effects immediately.

• Darzalex Faspro 1800mg is available in injection form and is advised to be taken as per the doctor's prescription. It should be administered by a doctor or experienced nurse under strict medical supervision.Taking this injection in the wrong way may give you severe side effects.
• In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention. Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.
  

• Darzalex Faspro 1800mg Injection contains Daratumumab as an active ingredient that is a targeted monoclonal antibody drug. This injection is designed to recognize & attach to specific proteins CD38 found on the surface of multiple myeloma cells.
• It works by binding to particular cancer cells and helps the Immmune system to kill them. Results in slow down the progression of cancer. 

• Kastritis, E., Palladini, G., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., ... & Comenzo, R. L. (2021). Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. New England Journal of Medicine, 385(1), 46-58. https://pubmed.ncbi.nlm.nih.gov/34192431/
• Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., ... & Sonneveld, P. (2016). Daratumumab, bortezomib, and dexamethasone for multiple myeloma. New England Journal of Medicine, 375(8), 754-766. https://pubmed.ncbi.nlm.nih.gov/27557302/
• Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., ... & Richardson, P. G. (2015). Targeting CD38 with daratumumab monotherapy in multiple myeloma. New England Journal of Medicine, 373(13), 1207-1219. https://pubmed.ncbi.nlm.nih.gov/26308596/
• Holzer, M. T., Ruffer, N., Huber, T. B., Kötter, I., Ostendorf, L., & Krusche, M. (2023). Daratumumab for autoimmune diseases: a systematic review. RMD open, 9(4), e003604. https://pubmed.ncbi.nlm.nih.gov/38101819/
• Nooka, A. K., Kaufman, J. L., Hofmeister, C. C., Joseph, N. S., Heffner, T. L., Gupta, V. A., ... & Lonial, S. (2019). Daratumumab in multiple myeloma. Cancer, 125(14), 2364-2382. https://pubmed.ncbi.nlm.nih.gov/30951198/